Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 178

Epigenetic Regulation of Cell Fate Reprogramming in H3K27M-altered ...

Diffuse midline glioma, including those located at the pons in the brainstem (diffuse intrinsic pontine gliomas, DIPGs) are childhood brain tumors and patients with DIPG have a poor prognosis with a median survival time less than 1 year from diagnosis. Currently, apart from radiation therapy, which partially slows down tumor growth, ...

OLIG2 Targeting in DIPG using the novel small molecular inhibitor ...

Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable brain stem glioma predominantly arising in young children, better options to treat this aggressive disease are urgently needed. Oligodendrocyte transcription factor 2 (OLIG2) is mostly expressed in restricted domains of the brain and spinal cord ventricular zone which give rise to oligodendrocytes and ...

Clinical, radiologic, and molecular characteristics of anaplastic pleomorphic xanthoastrocytomas

  Pleomorphic xanthoastrocytomas (PXAs) are uncommon brain cancers in children and young adults. World Health Organization (WHO) grade II PXAs (low-grade gliomas), which account for most such tumors, can be cured by complete surgery. Aggressive variants (i.e., anaplastic PXAs), which are rare, were only recognized by the WHO classification ...

Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for ...

This proposal is designed to help support a novel international clinical trial for children with the highly morbid brain tumor, Adamantinomatous Craniopharyngioma (ACP).  ACP is a solid/cystic tumor that originates in the sellar/suprasellar region at the base of the brain, adjacent to critical structures for vision, hormone ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...